Ebenezer A. Kio

机构：Indiana University Health, Goshen Health

发表论文 69 篇 · 总被引 1902 次 · h-index 15

代表论文

• Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial (2021 · Annals of Oncology · 被引 400)
• Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial (2019 · The Lancet Haematology · 被引 259)
• A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179 (2020 · Cancer · 被引 167)
• Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan (2017 · Clinical Cancer Research · 被引 163)
• SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer (2023 · Annals of Oncology · 被引 102)
• Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer (2016 · Clinical Cancer Research · 被引 82)